Actuate Therapeutics Inc (ACTU) is a clinical-stage biotechnology company developing cancer therapies, with a clean financial profile featuring zero debt and minimal liquidity assets relative to market cap. While business activities are fully permissible under Shariah principles, insufficient granular income data leads to conservative assessments in some areas. The company is not included in major Shariah indices due to its micro-cap status and clinical-stage risks, despite passing core financial screens. Overall, it presents low ESG risks and strong governance for its size, making it a potential candidate for compliant portfolios pending further data transparency.